Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study.

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Acta Diabetologica Pub Date : 2025-06-05 DOI:10.1007/s00592-025-02526-y

Jeremy Basset-Sagarminaga, Tim van den Heuvel, Javier Castañeda, Ohad Cohen

{"title":"Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study.","authors":"Jeremy Basset-Sagarminaga, Tim van den Heuvel, Javier Castañeda, Ohad Cohen","doi":"10.1007/s00592-025-02526-y","DOIUrl":null,"url":null,"abstract":"Aim: The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work).Methods: Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0-4, 4-8, 8-12, 12-16, 16-20 and 20-24 h after TT initiation).Results: CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods.Conclusions: These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Diabetologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00592-025-02526-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work).

Methods: Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0-4, 4-8, 8-12, 12-16, 16-20 and 20-24 h after TT initiation).

Results: CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods.

Conclusions: These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.

查看原文本刊更多论文

在美敦力MiniMed™780G高级混合闭环系统中使用临时血糖目标特征：一项真实世界的证据研究

目的：MiniMed™780G系统采用先进的混合闭环算法，优化后在葡萄糖目标浓度为100 mg/dL时表现最佳。该系统还包括一个150 mg/dL的临时目标特征（TT），可以在预期更高的葡萄糖利用率（例如，运动/剧烈工作）时设置。方法：使用1002名随机选择的MiniMed™780G和MiniMed™670G系统用户的真实世界数据来研究TT功能（n = 501个MiniMed™780G用户，n = 501个MiniMed™670G用户）。连续血糖监测（CGM）指标每隔4小时计算一次（TT开始前4小时和TT开始后0-4、4-8、8-12、12-16、16-20和20-24小时）。结果：CGM结果显示，两种系统在TT期的TIR大多等于或超过相应的非TT期的TIR。在TT启动后的前4小时，MiniMed™780G系统的TIR和近程时间（TITR）分别为71.6%和46.4%，[与670G系统相比，TIR和TITR分别提高了1.6 （p = 0.11）和2.6 （p = 0.009）个百分点]。在这两个时期，平均低于区间的时间仍然低于目标。结论：这些发现证实了TT设置的预期效果，允许用户在剧烈活动期间保持TIR而不影响安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Diabetologica 医学-内分泌学与代谢

CiteScore

7.30

自引率

2.60%

发文量

180

审稿时长

2 months

期刊介绍： Acta Diabetologica is a journal that publishes reports of experimental and clinical research on diabetes mellitus and related metabolic diseases. Original contributions on biochemical, physiological, pathophysiological and clinical aspects of research on diabetes and metabolic diseases are welcome. Reports are published in the form of original articles, short communications and letters to the editor. Invited reviews and editorials are also published. A Methodology forum, which publishes contributions on methodological aspects of diabetes in vivo and in vitro, is also available. The Editor-in-chief will be pleased to consider articles describing new techniques (e.g., new transplantation methods, metabolic models), of innovative importance in the field of diabetes/metabolism. Finally, workshop reports are also welcome in Acta Diabetologica.